Microneedling in Combination with Topical Pimecrolimus 1% versus Topical Pimecrolimus 1% for the Treatment of Refractory Stable Vitiligo: A Randomized Clinical Trial.
Journal
Dermatology research and practice
ISSN: 1687-6105
Titre abrégé: Dermatol Res Pract
Pays: Egypt
ID NLM: 101312803
Informations de publication
Date de publication:
2021
2021
Historique:
received:
22
09
2021
revised:
02
11
2021
accepted:
12
11
2021
entrez:
10
12
2021
pubmed:
11
12
2021
medline:
11
12
2021
Statut:
epublish
Résumé
Vitiligo is a common, autoimmune disease that results in the destruction of the melanocytes and manifests as depigmented macules on various areas of the skin. Numerous treatment options have been proposed for vitiligo. The purpose of this study was to compare the efficacy of microneedling plus topical pimecrolimus 1% versus the sole use of topical pimecrolimus 1% for the treatment of vitiligo. This clinical trial was conducted on 30 skin lesions on 15 Al-Zahra hospital patients. Each patient had two similar lesions in the limb area, and each lesion was considered a separate treatment group. The left or right side of the patient's lesion was randomly assigned to receive microneedling plus topical pimecrolimus for three months, while the other side received only topical pimecrolimus 1%. As part of the follow-up, digital photography was taken at the baseline and biweekly for three months after treatment and six months' follow-up. The following methods were used to evaluate the results: DLQI questionnaires, patient satisfaction questionnaires, and two independent dermatologists comparing the improvement rate for each group. Topical pimecrolimus 1% treatment led to unsatisfactory results, whereas the combination of microneedling and topical pimecrolimus1% treatment produced a more favorable overall outcome ( This study established that combination therapy results in more significant patient improvement. Additionally, one patient experienced mild skin irritation as a side effect of topical pimecrolimus.
Identifiants
pubmed: 34887918
doi: 10.1155/2021/5652140
pmc: PMC8651420
doi:
Types de publication
Journal Article
Langues
eng
Pagination
5652140Informations de copyright
Copyright © 2021 Fariba Iraji et al.
Déclaration de conflit d'intérêts
The authors declare no conflicts of interest regarding the publication of this paper.
Références
Dermatol Ther. 2021 Mar;34(2):e14750
pubmed: 33403790
Mov Disord. 2020 Jun;35(6):905-908
pubmed: 32347572
Adv Biomed Res. 2017 Mar 28;6:34
pubmed: 28516068
Exp Dermatol. 1993 Aug;2(4):145-53
pubmed: 8162332
J Am Acad Dermatol. 2011 Sep;65(3):493-514
pubmed: 21839316
J Eur Acad Dermatol Venereol. 2007 Nov;21(10):1369-74
pubmed: 17958843
Eur J Dermatol. 2007 Jan-Feb;17(1):55-61
pubmed: 17324829
Autoimmun Rev. 2016 Apr;15(4):335-43
pubmed: 26724277
J Cosmet Dermatol. 2019 Apr;18(2):581-588
pubmed: 30009490
JAMA Dermatol. 2019 Aug 1;155(8):929-938
pubmed: 31141108
Dermatol Surg. 2018 Mar;44(3):397-404
pubmed: 28796657
J Dtsch Dermatol Ges. 2006 Nov;4(11):942-6
pubmed: 17081269
Br J Dermatol. 2008 Nov;159(5):1051-76
pubmed: 19036036
Semin Cutan Med Surg. 2009 Jun;28(2):86-92
pubmed: 19608058
Dermatol Surg. 2012 Mar;38(3):381-91
pubmed: 22288899
Dermatol Ther. 2020 Nov;33(6):e14297
pubmed: 32940387
J Cosmet Dermatol. 2018 Oct;17(5):744-751
pubmed: 29532621
Dermatol Res Pract. 2011;2011:532139
pubmed: 21869882
Pigment Cell Res. 2003 Jun;16(3):208-14
pubmed: 12753387
J Am Acad Dermatol. 2016 Nov;75(5):e199-e200
pubmed: 27745652
J Cosmet Dermatol. 2018 Apr;17(2):165-170
pubmed: 28722334
Dermatol Res Pract. 2014;2014:240856
pubmed: 25221600
Dermatol Res Pract. 2019 Apr 2;2019:6879412
pubmed: 31065260